Related Experiment Video

Updated: Nov 29, 2025

Dynamic Light Scattering Analysis for the Determination of the Particle Size of Iron-Carbohydrate Complexes
04:40

Dynamic Light Scattering Analysis for the Determination of the Particle Size of Iron-Carbohydrate Complexes

Published on: July 7, 2023

2.9K

Ferric Carboxymaltose Across All Ages in Paediatric Gastroenterology Shows Efficacy Without Increased Safety Concerns

Natasha Sasankan1, Hazel Duncan1, Lee Curtis1

  • 1Royal Hospital for Children.

Journal of Pediatric Gastroenterology and Nutrition
|November 24, 2020
PubMed

Insights

Ferric carboxymaltose (FCM) effectively corrects iron deficiency anemia in pediatric gastroenterology patients. This treatment is safe and well-tolerated across all age groups, with minimal side effects when monitored carefully.

Area of Science:

  • Pediatric Gastroenterology
  • Hepatology
  • Nutrition
  • Hematology

Background:

  • Iron deficiency anemia (IDA) is a common condition in children, often requiring effective treatment.
  • Ferric carboxymaltose (FCM) is an intravenous iron formulation used for IDA.
  • Assessing FCM's efficacy and safety in pediatric gastroenterology is crucial.

Purpose of the Study:

  • To evaluate the efficacy and safety of ferric carboxymaltose (FCM) in treating iron deficiency anemia (IDA) in children and adolescents.
  • To determine the side-effect profile of FCM in this pediatric population.
  • To assess FCM's utility across various pediatric gastroenterology, hepatology, and nutrition indications.

Main Methods:

  • Retrospective study of pediatric gastroenterology patients (<18 years) treated with FCM from October 2015 to October 2017.
  • Collection and analysis of hematological and biochemical parameters pre-infusion and at multiple time points post-infusion (4 weeks, 3 months, 6 months, 1 year).
  • Documentation of any recognized side-effects associated with FCM administration.

Main Results:

  • Sixty-one pediatric patients received FCM, with a median age of 14 years.
  • Median hemoglobin increased significantly from 108 to 126 g/L at 1 month post-infusion (P < 0.00001).
  • 94% of children corrected their anemia; 3% reported minor side effects like bruising and staining.

Conclusions:

  • Ferric carboxymaltose (FCM) is an effective treatment for IDA in children across diverse gastroenterology indications and age groups.
  • FCM is generally well-tolerated, even in very young patients.
  • Careful monitoring during infusions can help prevent potential side effects.
Abstract

More Related Videos

The Caco-2 Cell Bioassay for Measurement of Food Iron Bioavailability06:34

The Caco-2 Cell Bioassay for Measurement of Food Iron Bioavailability

Published on: April 28, 2022

5.3K
Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

20.0K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
121
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
93
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
117
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
141
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
116
Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding01:15

Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding

Enteral nutrition encompasses various methods of delivering nutrition directly to the gastrointestinal (GI) tract, bypassing traditional oral intake. It is particularly beneficial for patients who cannot eat by mouth but have a functioning digestive system. Key methods include nasointestinal feeding, gastrostomy, and jejunostomy, each suited to different clinical scenarios based on the patient's needs and condition.
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube...
503